Global Overview on Heart Failure - Epidemiology Forecast to 2028 - ResearchAndMarkets.com

DUBLIN--()--The "Heart Failure: Epidemiology Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.

This report provides an overview of the risk factors and global trends of Heart Failure (HF) in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan and China). This report includes a 10-year epidemiological forecast for the diagnosed incident cases of Heart Failure (HF) and diagnosed prevalent cases of Chronic Heart Failure (CHF) segmented by age, sex, and ejection fraction.

The report also includes Acute Heart Failure (AHF) hospitalizations, prevalent cases of Chronic Heart Failure (CHF) segmented by New York Heart Association (NYHA) functional Classes I-IV and American College of Cardiology Foundation (ACCF)/American Heart Association (AHA) Stages.

Nearly 40% of all diagnosed prevalent cases of Chronic Heart Failure (CHF) in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan and China) occur in the elderly population, and this is estimated to increase by a further 40% by 2028. The major drivers for this trend include increasing life expectancy, early diagnosis of Heart Failure (HF) by improved screening and detection of Heart Failure (HF), as well as the widespread adoption of effective treatment strategies to manage Heart Failure (HF) patients with multiple comorbidities.

Diagnosed prevalent cases of Chronic Heart Failure (CHF) in the 8MM (US, France, Germany, Italy, Spain, UK, Japan and China) are projected to increase from 26.8 million in 2018 to 32.2 million in 2028, at an annual growth rate (AGR) of 2.02%. There were 12.8 million cases of the disease in China in 2018, which represented 47.69% of those in the 8MM (US, France, Germany, Italy, Spain, UK, Japan and China). The UK had the lowest number of diagnosed prevalent cases in 2018 at 5.50 million.

The substantial increase in comorbidities such as Coronary Artery Disease (CAD) and hypertension may be driving the number of diagnosed prevalent cases to rise in the elderly. It is observed that Heart Failure (HF) with preserved ejection fraction (PEF) is one of the common cardiac complications of longstanding hypertension. In 2018, the 8MM (US, France, Germany, Italy, Spain, UK, Japan and China) saw more than half of Chronic Heart Failure (CHF) patients experience Coronary Artery Disease (CAD) or hypertension as a major comorbid condition.

Despite advancements in the treatment of Chronic Heart Failure (CHF), the major unmet needs in elderly Chronic Heart Failure (CHF) patients are improved adherence to treatment guidelines and additional effective therapeutic options to manage Chronic Heart Failure (CHF) with multiple comorbidities. The improvement of screening techniques and diagnostic approaches over the years has led to better diagnoses, as reflected in the increased burden of Chronic Heart Failure (CHF). Effective strategies to prevent lifestyle diseases such as hypertension and diabetes mellitus during early adulthood may help prevent the occurrence of Chronic Heart Failure (CHF) in the elderly.

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global HF market.
  • Quantify patient populations in the global HF market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for HF therapeutics in each of the markets covered.
  • Understand magnitude of HF population by its severity.

Key Topics Covered:

1 Heart Failure: Executive Summary

1.1 Related Reports

1.2 Upcoming Reports

2 Epidemiology

2.1 Disease Background

2.2 Risk Factors and Comorbidities

2.3 Global and Historical Trends

2.4 Forecast Methodology

2.4.1 Sources

2.4.2 Forecast Assumptions and Methods: Diagnosed Incident Cases of HF

2.4.3 Forecast Assumptions and Methods: Diagnosed Incident Cases of HF by EF

2.4.4 Forecast Assumptions and Methods: Acute Hospitalizations

2.4.5 Forecast Assumptions and Methods: Acute Hospitalizations by Worsening CHF, Advanced HF, and De Novo HF

2.4.6 Forecast Assumptions and Methods: Hospital Length of Stay

2.4.7 Forecast Assumptions and Methods: Hospital Readmissions (Within 30 Days) Post-Discharge After AHF Hospitalization

2.4.8 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of CHF

2.4.9 Diagnosed Prevalent Cases of CHF by EF

2.4.10 Diagnosed Prevalent Cases of CHF by NYHA Classes

2.4.11 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of CHF by ACCF/AHA Stages

2.5 Epidemiological Forecast for Heart Failure (2018-2028)

2.5.1 Diagnosed Incident Cases of HF

2.5.2 Age-Specific Diagnosed Incident Cases of HF

2.5.3 Sex-Specific Diagnosed Incident Cases of HF

2.5.4 Diagnosed Incident Cases of HF by EF

2.5.5 AHF Hospitalizations

2.5.6 Hospital Length of Stay for AHF Hospitalization

2.5.7 Hospital Readmissions (Within 30 Days) Post-Discharge After AHF Hospitalization

2.5.8 Diagnosed Prevalent Cases of CHF

2.5.9 Diagnosed Prevalent Cases of CHF by EF

2.5.10 Age-Specific Diagnosed Prevalent Cases of CHF

2.5.11 Sex-Specific Diagnosed Prevalent Cases of CHF

2.5.12 Diagnosed Prevalent Cases of CHF by NYHA Class

2.5.13 Diagnosed Prevalent Cases of CHF with PEF by NYHA Class

2.5.14 Diagnosed Prevalent Cases of CHF with REF by NYHA Class

2.5.15 Diagnosed Prevalent Cases of CHF by ACCF/AHA Classification

2.6 Discussion

2.6.1 Epidemiological Forecast Insight

2.6.2 Limitations of the Analysis

2.6.3 Strengths of the Analysis

3 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/eurr3g

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900